Suzanne Handler, MD
Ophthalmology · San Diego, CANPI 1851307797
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 360 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Alcon at 27.2% of the total. 2025 is the largest year on record at $3,116, 6.7 times the $464 reported in 2019.
Across 360 payments — averaging $30.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Amgen$1K
- AbbVie$1K
- Bausch & Lomb Americas Inc.$768
- Sight Sciences, Inc.$610
- Tarsus Pharmaceuticals, Inc.$559
- plus $3K from 18 others
What the payments were for
- Food & beverage$10,943100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 80 | $2,985 |
| Amgen(2 entities) | 35 | $1,498 |
| AbbVie(2 entities) | 68 | $1,151 |
| Bausch & Lomb Americas Inc. | 37 | $768 |
| Sight Sciences, Inc. | 11 | $610 |
| Tarsus Pharmaceuticals, Inc. | 18 | $559 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $528 |
| Dompe US, Inc. | 13 | $448 |
| Mallinckrodt Hospital Products Inc. | 13 | $406 |
| Harrow Eye, LLC | 11 | $377 |
| Rxsight Inc | 4 | $296 |
| Glaukos Corporation | 8 | $218 |
| Aerie Pharmaceuticals, Inc. | 8 | $215 |
| Oyster Point Pharma, Inc. | 7 | $158 |
| Novartis | 8 | $155 |
| Biotissue Holdings Inc. | 6 | $140 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $100 |
| Sun Pharmaceutical Industries Inc. | 4 | $98 |
| Kala Pharmaceuticals, Inc. | 4 | $81 |
| Thea Pharma Inc. | 4 | $67 |
| Ocular Therapeutix, Inc. | 2 | $32 |
| AstraZeneca | 1 | $30 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Lumenis, Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,173
- TEPEZZA$998
- OMNI(R) SURGICAL SYSTEM (US)$410
- Tecnis IOL$380
- Clareon PanOptix Pro$246
- XDEMVY$239
- Hydrus Microstent$220
- Oxervate$133
- VEVYE$127
- MIEBO$125
- XIIDRA$125
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
- Rocklatan$121
- Rhopressa$121
- AcrySof$120
- RXSIGHT CONTACT LENS$113
- RXSIGHT INJECTOR HANDPIECE$113
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$113
- RXSIGHT INJECTOR CARTRIDGE$113
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$113
How this compares
$10,963 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 83 | $96,388 |
| RestasisCyclosporine | 38 | $44,885 |
| LumiganBimatoprost | 84 | $33,702 |
| MieboPerfluorohexyloctane/Pf | 35 | $32,418 |
| ProlensaBromfenac Sodium | 61 | $20,537 |
| RhopressaNetarsudil Mesylate | 18 | $8,863 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $7,775 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $4,248 |
| MoxifloxacinMoxifloxacin Hcl | 167 | $3,180 |
| Travoprost | 22 | $3,155 |
| Latanoprost | 293 | $3,098 |
| Prednisolone Acetate | 40 | $1,481 |
| Brimonidine Tartrate | 17 | $1,378 |
| Fluorometholone | 20 | $1,215 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 63 | $881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $768 | $128,806118 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,151 | $86,362143 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $100 | $20,53761 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $215 | $8,86318 claims |
| AlconSimbrinza | $2,985 | $4,24821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Diego
- Robert WeinrebSan Diego$520K
- Eric NudlemanSan Diego$343K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.